Levaquin Settlements and Jury Awards
Thousands of Americans have filed lawsuits with hopes of winning significant Levaquin settlements or jury awards.
More than 13.5 million Levaquin prescriptions were dispensed in 2007, a year before the FDA required the popular antibiotic carry a “black box” warning for tendonitis and tendon rupture.
Millions of prescriptions have been written since, with thousands of patients reporting Levaquin tendon ruptures.
Levaquin jury verdict in excess of $ 1 million
At least one plaintiff has come away with a million dollar Levaquin settlement against drugmaker Ortho-McNeil-Janssen, a subsidiary of Johnson & Johnson.
John Schedin, an 82-year-old from Minnesota, was prescribed Levaquin in 2005 to treat an upper respiratory infection. At the time, Schedin was an active senior, playing golf several times a month. While taking Levaquin, Schedin ruptured both of his Achilles tendons, leaving him unable to climb stairs and severely impairing his mobility.
In December 2010, a Minnesota jury awarded him $1.8 million in compensatory and punitive damages.
Next Levaquin trial begins April 11
The next Levaquin trial is scheduled to begin April 11. Johnson & Johnson may choose to reach a settlement with the plaintiff before the trial gets underway.
It is possible that J&J has reached confidential Levaquin settlements with countless plaintiffs involved in the litigation. As more cases go to trial and juries rule in favor of plaintiffs, the likelihood grows that Johnson & Johnson will seek to reach Levaquin settlements with more than 2,600 plaintiffs who have so far filed Levaquin lawsuits.
That number may grow as news of Levaquin’s risks continue to make headlines.
Given the nearly $ 1 billion in annual Levaquin sales, Johnson & Johnson could be on the hook for an incredible sum.
As the Schedin decision shows, individual plaintiffs may also be eligible to receive Levaquin settlement amounts or jury verdicts in excess of $ 1 million.
Representatives for Johnson & Johnson have said they will appeal the Schedin decision. The appeal is a risky move for the drugmaker who stands to pay out even more if the appeal is denied.